1029877-94-8

1029877-94-8 structure

Name: Trelagliptin succinate
Chemical Name: 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioic acid
CAS Number: 1029877-94-8
Molecular Formula: C₂₂H₂₆FN₅O₆
Molecular Weight: 475.470
Catalog: Pharmaceutical intermediate API intermediate
Create Date: 2018-07-01 16:12:11
Modify Date: 2024-01-02 09:36:34
Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.

Name	2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioic acid
Synonyms	Trelagliptin (succinate) Trelagliptin succinate [USAN] Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluoro-, butanedioate (1:1) SYR472 succinate Zafatek SYR 472 2-({[6-[(3R)-3-aminopipidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)- yl}methyl)-4-fluorobenzonitrile hydrogen butanedioate Succinic acid - 2-({6-[(3R)-3-amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile (1:1) SYR111472 Succinate SYR-472

Description	Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase Research Areas >> Metabolic Disease
References	[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus [2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus [3]. Long-term Study of SYR-472 [4]. SYR-472 Open-label Study

Hazard Codes	Xi